Cardiac magnetic resonance imaging in hemodialysis patients

Journal of Nephrology

Volumn 22, Issue 3, 2009, Pages 367-372

  McGill, Rita L ^a   Biederman, Robert W W ^a   Getts, Roger T ^a   Hazlett, Shawn M ^a   Sharma, Sandeep B ^a   Duran, Jonathan ^a   Brandys, Dana E ^a   Sysak, Joshua C ^a   Sureshkumar, Kalathil K ^a   Sandroni, Stephen E ^a   Marcus, Richard J ^a  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Cardiac MRI; ESRD; Left ventricular hypertrophy; Spironolactone

Indexed keywords

POTASSIUM; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMODIALYSIS PATIENT; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; POTASSIUM BLOOD LEVEL; CHRONIC KIDNEY FAILURE; METHODOLOGY; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; SPIRONOLACTONE;

EID: 69449105794     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Middleton RJ, Parfrey PS, Foley RN. Left ventricular hypertrophy in the renal patient. J Am Soc Nephrol. 2001;12:1079-1084.
2. Foley RN, Parfrey PS, Kent 2. GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int. 1998;54:1720-1725.
3. deSimone G. Left ventricular geometry and hypotension in end-stage renal disease: a mechanical perspective. J Am Soc Nephrol. 2003;14:2421-2427.
4. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. The CONSENSUS Trial Study Group. Circulation. 1990;82:1730-1736.
5. Weber, KT. Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation. 1997;96:4065-4082.
6. Brilla CG, Matsubara LS, Weber KT. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol. 1993;25:563-575.
7. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
8. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure New Engl J Med. 1999;341:709-717.
9. RALES Investigators. Effectiveness of spironolactone added to an angiotensin converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol. 1996;78:902-907.
10. Sato A, Hayahi M, Saruta T. Relative long-term effects of spironolactone in conjunction with an angiotensin-converting enzyme inhibitor on left ventricular mass and diastolic function in patients with essential hypertension. Hypertens Res. 2002;25:837-842.
11. deResende MM, Kriegel AJ, Greene AS. Combined effects of low-dose spironolactone and captopril therapy in a rat model of genetic hypertrophic cardiomyopathy. J Cardiovasc Pharmacol. 2006;48:265-273.
12. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man: anatomic validation of the method. Circulation. 1977;55:613-618.
13. Stewart GA, Foster J, Cowan M, et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int. 1999;56:2248-2253.
14. Hunold P, Vogt F, Heemann UW, Zimmermann U, Barkhausen J. Myocardial mass and volume measurement of hypertrophic left ventricles by MRI: study in dialysis patients examined before and after dialysis. J Cardiovasc Magn Reson. 2003;5:553-561.
15. Hussain S, Dreyfus DE, Marcus RJ, Biederman RW, McGill RL. Is spironolactone safe for dialysis patients? Nephrol Dial Transplant. 2003;18:2364-2368.
16. Aoki J, Ikari Y, Nakajima H, et al. Clinical and pathologic characteristics of dilated cardiomyopathy in hemodialysis patients. Kidney Int. 2005;67:333-340.
17. Covic A, Gusbeth-Tatomir P, Goldsmith DJ. Is it time for spironolactone therapy in dialysis patients? Nephrol Dial Transplant. 2006;21:854-858.
18. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer S. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. J Cardiovasc Magn Reson. 2005;7:775-782.
19. Li W, Stern JS, Mai VM, Pierchala LN, Edelman RR, Prasad PV. MR assessment of left ventricular function: quantitative comparison of fast imaging employing steady-state acquisition (FIESTA) with fast gradient echo cine technique. J Magn Reson Imaging. 2002;16:559-564.
20. Gerdes AM, Capasso JM. Structural remodeling and mechanical dysfunction of cardiac myocytes in heart failure. J Mol Cell Cardiol. 1995;27:849-856.
21. London GM. Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant. 2002;17(Suppl 1):29-36.
22. Mark PB, Johnston N, Groenning BA, et al. Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int. 2006;69:1839-1845.